New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population. In HIV/HCV coinfected population, the study of HIV reservoir dynamics and the analysis of the prevalence of HCV resistance-associated mutations will help clinicians to improve the management of coinfected patients.
New markers of viral activity are now under investigation. Besides HIV-RNA and CD4 cells count, HIV-DNA is an emerging marker of viral reservoir, that seems to be associated with the risk of HIV-related diseases, especially in HCV coinfected patients. New antiretroviral drugs, particularly integrase inhibitors, are expected to decrease residual viremia and, consequently, viral reservoir. Monitoring of HIV-DNA dynamics during antiretroviral treatment could lead to a better management of HIV infected population. Also, the role of HCV in influencing HIV natural history requires careful monitoring. In particular, with a broader use of direct acting antiretroviral, the analysis of prevalence of HCV resistance associated mutation will be more and more important to manage patients with treatment failure.
Study Type
OBSERVATIONAL
Enrollment
600
Blood withdrawal for HIV-DNA or HCV resistance test
Catholic University of Sacred Heart
Rome, Italy
RECRUITINGPercentage of HIV-positive patients with a significant HIV-DNA decay after 3 years from a new antiretroviral regimen start
Time frame: up to 144 weeks
Percentage of HIV/HCV coinfected patients with a significant HIV-DNA decay after 3 years from the enrollment
Time frame: up to 144 weeks
Measurement of HIV-DNA level during HCV antiviral therapy with DAA in HIV/HCV coinfected patients
Time frame: up to 24 weeks
Prevalence of HCV resistance-associated variants and their relation with HIV-DNA levels in HIV/HCV coinfected patients, treated or not treated for HCV.
Time frame: up to 144 weeks
Comparison of the prevalence of HCV resistance-associated variants in HIV/HCV coinfected population versus HCV monoinfected population
Time frame: up to 144 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.